There is no cure for multiple sclerosis. No treatment can fully eliminate the disease or reverse all the damage it causes. But the gap between “no cure” and “no hope” has narrowed dramatically over the past two decades. More than 20 approved therapies can slow or even halt the disease’s progression, and several experimental approaches are targeting something once thought impossible: repairing the nerve damage MS leaves behind. Around 2.8 million people worldwide live with MS, and for many of them, modern treatment means living a largely normal life for decades.
Why MS Is So Hard to Cure
MS is an autoimmune disease in which the immune system attacks myelin, the protective coating around nerve fibers in the brain and spinal cord. Myelin works like insulation on electrical wiring. When it’s stripped away, nerve signals slow down or stop entirely, producing symptoms that range from numbness and fatigue to difficulty walking and vision problems. The challenge with curing MS is twofold: stopping the immune system from continuing the attack, and repairing myelin that’s already been destroyed. Current treatments handle the first part reasonably well. The second remains one of the biggest unsolved problems in neurology.
What Today’s Treatments Can Do
The current standard of care centers on disease-modifying therapies, a class of drugs designed to reduce the frequency and severity of relapses and slow the accumulation of disability over time. There are now more than 20 FDA-approved options, available as injections, oral pills, or intravenous infusions. Some work by broadly calming the immune system, while newer options are more targeted, depleting specific immune cells that drive the attack on myelin or trapping immune cells in lymph nodes so they can’t reach the brain.
These treatments don’t repair existing damage, and they don’t work equally well for everyone. But for people with relapsing forms of MS (the most common type), starting treatment early can make a significant difference. People diagnosed today have a median life expectancy of about 74.7 years, compared to 81.8 years in the general population. That seven-year gap, while real, is considerably smaller than it was a generation ago, when fewer treatments existed and diagnosis often came later.
Stem Cell Transplant: The Closest Thing to Remission
The most aggressive treatment currently available is autologous hematopoietic stem cell transplant, or HSCT. The procedure essentially reboots the immune system. Doctors collect stem cells from your blood, use chemotherapy to wipe out your existing immune system, then reinfuse the stem cells to rebuild it from scratch. The goal is to eliminate the rogue immune cells attacking myelin and replace them with a fresh immune system that doesn’t target the brain.
The results can be striking. In patients with relapsing-remitting MS, about 62% showed no evidence of disease activity (no relapses, no new brain lesions, no worsening disability) five years after transplant. At ten years, that number dropped to around 40%, meaning some patients eventually experienced new disease activity. With the most intensive treatment protocols, outcomes were better: roughly 55% maintained that disease-free status at ten years.
HSCT isn’t a cure in the technical sense, since the disease can return, and it carries serious risks. The chemotherapy phase suppresses the immune system completely, leaving patients vulnerable to infections. It’s generally reserved for people with aggressive MS who haven’t responded well to other treatments, particularly younger patients with relapsing disease. But for a subset of people, it offers years or even decades without medication and without disease progression.
Myelin Repair: Treating the Damage, Not Just the Attack
Most MS treatments focus on suppressing the immune system. A newer line of research asks a different question: can the brain be coaxed into repairing the myelin it’s already lost? In 2014, researchers at UC San Francisco discovered that an obscure over-the-counter antihistamine called clemastine could activate dormant repair cells in the brain. These cells, called oligodendrocyte precursor cells, sit quietly in the brain and spinal cord until they sense injured tissue. When activated, they mature into cells that produce new myelin.
Clemastine worked, but imprecisely. It hit multiple receptors in the brain, and its effect on the one that mattered most was modest. That discovery led to the development of PIPE-307, a purpose-built drug designed to potently block that single receptor, cross the blood-brain barrier efficiently, and prompt repair cells to mature and begin wrapping new myelin around exposed nerve fibers. PIPE-307 is currently in clinical testing. If it works in humans, it would represent a fundamentally new category of MS treatment: one that restores function rather than just preventing further loss.
The Epstein-Barr Virus Connection
One of the most significant MS discoveries in recent years is the strong link between Epstein-Barr virus (EBV) and the disease. EBV is the virus that causes mono, and nearly everyone is infected with it at some point in life. But research has shown that EBV infection dramatically increases the risk of developing MS, and some scientists believe it may be a necessary trigger for the disease in genetically susceptible people.
This connection has opened an entirely different avenue toward prevention. Several groups are working on EBV vaccines, with the idea that vaccinating children before they encounter the virus could prevent MS from ever developing. Researchers are also exploring therapeutic vaccines designed to target EBV-infected immune cells that may be driving the disease in people who already have MS. If the causal link is confirmed, an effective EBV vaccine could reduce the incidence of MS the way childhood vaccines have reduced measles and polio.
New Drug Classes in Late-Stage Testing
A class of drugs called BTK inhibitors is generating significant interest because they may work differently from existing therapies. There are currently 11 phase 3 clinical trials testing four different BTK inhibitors in MS. What makes these drugs notable is their potential to treat progressive forms of the disease, not just the relapsing type. Two of these drugs, tolebrutinib and fenebrutinib, are being tested specifically in primary progressive MS and nonrelapsing secondary progressive MS, forms of the disease that have very few treatment options today. These drugs work inside the brain rather than just in the bloodstream, which may allow them to target the smoldering inflammation that drives progressive disability even when relapses have stopped.
Managing Symptoms Day to Day
While researchers work toward better treatments and potential cures, daily management plays a real role in how MS affects quality of life. Regular exercise, particularly walking, swimming, yoga, and stationary cycling, improves strength, balance, and coordination. Swimming is especially useful because water keeps your body cool, and heat can temporarily worsen MS symptoms. Cooling vests and scarves can help during warmer months for the same reason.
A Mediterranean-style diet (heavy on fruits, vegetables, whole grains, olive oil, and legumes, light on red meat and sugar) is linked to lower risk of worsening disability. Vitamin D supplementation at 2,000 to 5,000 international units daily is commonly recommended for people with MS, based on research suggesting a potential protective benefit. Stress management through meditation, deep breathing, or tai chi matters too, since stress can trigger or worsen symptom flares. And quality sleep is more important than it might seem: fatigue is one of the most common and disabling MS symptoms, and poor sleep habits make it worse.
Where Things Stand
MS remains an incurable disease, but the meaning of that word is shifting. A person diagnosed in 2025 has access to treatments that can keep the disease quiet for years or decades. Stem cell transplant offers drug-free remission for a meaningful percentage of patients. Myelin repair drugs could eventually restore lost function. And an EBV vaccine might one day prevent the disease entirely in future generations. The honest answer to “is there a cure” is still no. But for the first time, the research pipeline contains approaches that look less like management and more like something approaching one.